Last Updated 28 September 2015 The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The…
Schizophrenia is a chronic, severe mental illness characterized by a range of symptoms that include positive symptoms (e.g., delusions, hallucinations), negative symptoms (e.g., affective…
Physician and Payer Attitudes and the Impact of the Aging Population Aging is considered a new healthcare challenge globally, and Alzheimer’s disease (AD) is one of the most debilitating…
Schizophrenia is an often disabling psychiatric disease whose core treatment consists of up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical…
Alzheimer’s disease (AD) is one of the most common neurological conditions in the elderly and imparts considerable strain on worldwide healthcare resources. For the estimated 2 million people in…
Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration, as well as behavioral and/or psychological…
What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…
What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…